Back to News
investment

FDA declines to issue specific guidance on health programs' foreign drug imports

CNBC
Loading...
3 min read
0 likes
⚡ Quantum Brief
The FDA refused to clarify laws banning foreign prescription drug imports despite growing use of alternative funding programs (AFPs) that source cheaper medications overseas for U.S. patients with unmet health needs. A 2024 citizen petition from non-profit Aimed Alliance urged the FDA to issue guidance on AFPs, citing risks like counterfeit or contaminated drugs, but the agency called it an inefficient use of resources. The FDA acknowledged safety concerns in a March 2026 letter but declined enforcement action, stating such requests fall outside citizen petition procedures, leaving legal ambiguity intact. AFPs argue they provide critical, affordable drugs, while Homeland Security officials call their practices illegal, per a 2025 CNBC investigation revealing widespread program expansion nationwide. Patient advocacy groups continue pushing for stricter oversight, but the FDA’s inaction maintains regulatory uncertainty around foreign-sourced medications for cost-burdened patients.
AI Audio Summary
0:00 / 0:00
Click to play
growtika-TKAg3WignSw-unsplash.jpg
Quantum News · Media Library

The Food and Drug Administration in recent weeks said it would decline to clarify laws that ban the foreign importation of prescription medicines, despite growing evidence of the overseas schemes. A class of businesses called alternative funding programs, or AFPs, connect patients whose health plans don't cover expensive medications for critical diseases with more affordable versions of the drugs. The programs obtain the medications from foreign markets in what U.S. regulators say is a violation of import laws.The FDA last month responded to a March 2024 citizen petition from Aimed Alliance, a non-profit health policy organization, that requested the agency to issue a definitive position on AFPs and the use of international importation to save on drug costs. Specifically, the Alliance wanted the FDA to issue a "guidance document" aimed at AFPs that import drugs from overseas, which would have further clarified the agency's policy and potentially eliminated some gray area in the interpretation of the laws.In the letter, dated March 27, the FDA said it shared the Alliance's concerns and acknowledged drugs that have "circumvented regulatory safeguards may be contaminated, counterfeit, or contain varying amounts of active ingredients altogether."But it denied the group's request for a clear position statement and specific guidance about AFPs, saying that "it's not warranted at this time." The agency said "it would not be an efficient use of FDA's limited resources" to issue that guidance."We take complaints seriously and appreciate the information that you have provided. However, to the extent you are asking FDA to initiate an enforcement action, such actions are not within the scope of FDA's citizen petition procedures," the letter said.The letter was signed by Michael Davis, deputy director for the FDA's Center for Drug Evaluation and Research.Aimed Alliance is one of several patient advocacy groups that have asked the FDA to crack down on AFPs using foreign sources to import medications. The Alliance did not immediately respond to a request for comment from CNBC. A CNBC investigation in November revealed the proliferation of AFPs across the country. As part of that investigation, a Homeland Security Investigations official said AFP practices were illegal, while the program operators maintain they are not breaking the law and help patients obtain critical drugs for little or no cost.Got a confidential news tip? We want to hear from you.Sign up for free newsletters and get more CNBC delivered to your inboxGet this delivered to your inbox, and more info about our products and services.© 2026 Versant Media, LLC.

All Rights Reserved. A Versant Media Company. Data is a real-time snapshot *Data is delayed at least 15 minutes. Global Business and Financial News, Stock Quotes, and Market Data and Analysis. Data also provided by

Read Original

Source Information

Discussion

0 professional contributions

Sign in to join this professional discussion.

Be the first to add a constructive contribution.